Clinical trial · no report yet · Phase 2
PAXIPEM
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
- NCT05096390 ↗
- Unknown
- Centre Leon Berard
- 8 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| X threads | 3 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Papillary Renal Cell Carcinoma Type 2
- Interventions
- Axitinib Oral Tablet [Inlyta]; Pembrolizumab Injection [Keytruda]
- Arms
- axitinib + pembrolizumab · Experimental
- axitinib alone (control) · Active comparator
- Enrollment
- 72 (estimated)
- Primary outcomes
- Efficacy of axitinib + pembrolizumab versus axitinib in patients with locally advanced or metastatic type 2 papillary renal carcinoma in first-line treatment.
- Sponsor
- Centre Leon Berard
- Start
- Jun 1, 2022
- Primary completion
- Oct 2024 (estimated)
- Results posted
- No
- Registry record
- NCT05096390 · updated Jan 25, 2024